DOCSLIB.ORG

Drug Developement

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Developement DRUG DEVELOPEMENT 2 Summary Acronyms used in preclinical development Life cycle of medicine Clinical trials for Beginners The Funnel Road map Example of drug development: Chemical level Pharmaceutical level Preclinical pharmacology Preclinical Toxicology Preclinical ADME 3 Preclinical development acronyms (1) ADME Absorption, distribution, metabolism, and excretion API Active pharmaceutical ingredient: any component intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease. CFR Code of Federal Regulations CGMP, GMP (Current) good manufacturing practice CMC Chemistry manufacturing and controls CoA Certificate of analysis CRO Contract research organization CTM Clinical trial material Cmax Maximum plasma concentration 4 Preclinical development acronyms (2) DP Drug product: finished dosage form (for example, tablet, capsule, solution) that contains an active drug ingredient, generally in association with inactive ingredients DS Drug substance: any substance that is represented for use in a drug and that, when used in manufacturing, processing, or packaging of a drug, becomes an active ingredient or a finished drug form FDA US Food and Drug Administration FIH First in human FRS Foreign related substances GLP Good laboratory practice HPLC High performance liquid chromatography ICH International Conference on Harmonization IND Investigational New Drug application MTD Maximum tolerated dose NCE New chemical entity 5 Preclinical development acronyms (3) NDA New drug application NCI National Cancer Institute NIA National Institute on Aging NOAEL No observed adverse effect level PIB Powder in bottle PK Pharmacokinetics RAID Rapid Access to Intervention Development (preclinical program) SBIR Small Business Innovative Research (grant) STTR Small Business Technology Transfer (grant) TI Therapeutic Index TK Toxicokinetic Tmax Time of maximum plasma concentration after dose administration TTP Target product profile 6 Drug development for beginners 7 8 9 The Funnel Translating a Discovery into a Product 10 Typical problems 11 'begin with the end in mind This adage is particularly appropriate for preclinical development, as the resulting IND must support the planned clinical trial design. For example, a clinical trial involving daily chronic administration requires repeat-dose toxicity studies in preclinical animal models. 12 Road map The drug development process is typically divided into three major steps: Discovery, Preclinical development, and Clinical trial. Preclinical development Research and Development Product development Preclinical studies Toxicology studies (PK, ADME) GLP toxicology studies IND package 13 Ethical Principles in Preclinical Study 14 Requirement to publish Experiments should be conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals and should have the approval of the Ethics Committee for Animal Experiments. 15 Ethics for experimental studies AMERICAN UNIVERSITY OF Public and private research in France BEIRUT: INSTITUTIONAL has established ethics committees ANIMAL CARE AND USE that analyze experimental protocols COMMITTEE submitted to them. REQUEST FORM FOR RESEARCH The committees may ask researchers PROTOCOL APPROVAL to develop protocols to reduce or Search for Alternatives: eliminate, if possible, any animal FRAME Guide to Searching suffering. for Alternatives to the Use of Laboratory Animals This is an additional guarantee for the civil society about the scientific justification of experiences and animal welfare Search for alternatives is encouraged! 16 Binding study Cell test Animal models Toxicology study Preclinical evaluation Investigational New Drug application summarizes the results of the above activities for submission to the US FDA 17 IND Table of Contents 1. Form FDA 1571 [21 CFR 312.23(a)(1)] 2. Table of contents [21 CFR 312.23(a)(2)] 3. Introductory statement [21 CFR 312.23(a)(3)] 4. General investigational plan [21 CFR 312.23(a)(3)] 5. Investigator's brochure [21 CFR 312.23(a)(5)] 6. Protocol(s) [21 CFR 312.23(a)(6)] a. Study protocols [21 CFR 312.23(a)(6)] b. Investigator data [21 CFR 312.23(a)(6)(iii)(b)]a c. Institutional review board data [21 CFR 312.23(a)(6)(iii)(b)]a 7. Chemistry, manufacturing, and control data[21 CFR 312.23(a)(7)] 8. Pharmacology and toxicology data [21 CFR 312.23(a)(8)] 9. Previous human experience [21 CFR 312.23(a)(8)] 10. Additional information [21 CFR 312.23(a)(10)] 18 Discoveries during last years Anti-TNF in auto-immune disease (PR) AIDS: 5 mechanism of action Cardiology : prevention – NOAC (Dabigatran/Rivaroxaban/Apixaban) Anti-Alzheimer: Bapineuzumab New anticancer drugs: Tinibs 19 2003 Blockbusters at the Drugstore (US/Worldwide; out of ~$500b) Lipitor (Pfizer) cholesterol $6.8/10.3 billion (66%) Zocor (Merck) cholesterol $4.4/6.1 billion (72%) Zyprexa (Eli Lilly) antipsychotic $3.2/4.8 billion (72%) Norvasc (Pfizer) blood pressure $2.2/4.5 billion (40%) Procrit (J&J) anemia $3.3/4.0 billion (83%) Prevacid (TAP) ulcers $4.0/4.0 billion (100%) Nexium (AstraZeneca) ulcers $3.1/3.8 billion (82%) Plavix (BMS-Sanofi) blood thinner $2.2/3.7 billion (59%) Seretide (GSK) asthma $2.3/3.7 billion (62%) Zoloft (Pfizer) depression $2.9/3.4 billion (85%) Epogen (Amgen) anemia $3.1/? billion (?%) Celebrex (Pfizer) arthritis $2.6/? billion (?%) Source: IMS Health, March 2004 20 Me too drugs: antidepressants 1986 Fluvoxamine (Luvox; Solvay) SSRI 1987 Fluoxetine (Prozac; Lilly) SSRI 1992 Sertraline* (Zoloft; Pfizer) SSRI/NRI 1993 Venlafaxine (Effexor; Wyeth) SSRI/NRI 1996 Buproprion (Wellbutrin; Wyeth) SNRI/DRI 2002 Escitalopram (Lexapro; Forrest) SSRI 2004 Duloxetine (Cymbalta; Lilly) SSRI/NRI 21 “Big Pharma” Drug Discovery in the 21st Century The pharmaceutical industry is short of new drugs. In the 2nd part of the 20th century, about 50-60 new drugs (NCEs) were approved by the FDA every year. In contrast, in 2002, a historical low of 18 NCEs were approved (in 2001, 24 NCEs, in 2000, 27 NCEs, in 2003, 21 NCEs). Conversely, research costs for a new drug are estimated to be in the $1-1.5 Bi. range. 22 Clinical Trial: Phase I In Phase 1, we seek to understand what the organism does to the new molecule, which is also known as 1. pharmacokinetics: Healthy volunteers, Bioavailability and the best route of administration. 2. Research for the right dose. 3. In fact, the primary objective is to ascertain safety. Thirty percent of synthesized molecules is lost in Phase 1. 23 Clinical Trial: Phase II It is called the therapeutic exploratory phase. In Phase 2, we seek to establish the efficacy of a drug (in subjects) with a specific illness. We also compare how the illness responds to established standard drugs or to a placebo. Phase 2 studies also allow us to determine the level of short-term safety and range of appropriate dosage. Test in a relatively small population of about 300 to 500 patients. That is where the wisdom of clinical researchers is found. 24 Clinical Trial: Phase III This phase is also known as the therapeutic confirmatory phase. It consists of large-scale studies designed to find the efficacy and safety of the new drug relative to already accepted drugs. Thousands of subjects are involved at this point, including people from different populations. These studies are usually controlled with a placebo or with drugs that are universally accepted for treating that specific condition. Phase 3 studies allow us to build a good profile of how the drug behaves when it is used in large populations. 25 Clinical Trial: Phase IV The drug is submitted to health authorities and if it is approved, the phase 4 begins. It consists of studies that differentiate the investigational drug from other drugs in its class; studies that compare the drug’s efficacy and demonstrate the drug’s benefits in terms of pharmaco-economics. Phase 4 is never-ending. 26 27 Remarks Transition from discovery to preclinical development is a continuum, and results of preliminary pharmacology and toxicology testing often contribute to lead drug candidate selection. Preclinical development encompasses the activities that link drug discovery in the laboratory to initiation of human clinical trials. Investigational New Drug application 28 Preclinical drug development stages. Following identification of a drug target and candidate compounds, several early activities, such as pharmacology, in vivo efficacy, and experimental toxicology, can contribute to the selection of a lead candidate for preclinical development. These preclinical activities provide the basis for an Investigational New Drug (IND) application to the FDA for permission to initiate clinical testing in humans. ADME, absorption, distribution, metabolism, and excretion; API, active pharmaceutical ingredient; PK, pharmacokinetics; Prep, preparation; Tox, toxicity. 29 Lead product Once a lead candidate is identified, a typical preclinical development program consists of six major efforts: Manufacture of drug substance (DS)/active pharmaceutical ingredient (API); Pre-formulation and formulation (dosage design); Analytical and bio-analytical methods development and validation; Metabolism and pharmacokinetics; Toxicology, both safety and genetic toxicology and possibly safety pharmacology; And good manufacturing practice (GMP) manufacture and documentation of drug product for use in clinical trials. 30 Time is money 31 Dépenses en R&D 32 DRUG DISCOVERY 33 Medicinal Chemistry The science that deals with the discovery or design of new therapeutic agents and their development into useful medicines. It involves: Synthesis Structure-Activity Relationships (SAR) Receptor interactions 34 2003 Blockbusters at the Drugstore HO O O (US/Worldwide; out of ~$500b) CH3 O N N O H N OH H OH N O N H H O Zyprexa CH3 OH N H C Lipitor H S CH3 3 F Zocor O H N OH 2 S O O N Ph H HO (H2C)4 N N S N O CF3 HN O CF3 HO N CH3 (CH2)6 OH Prevacid Seretide CO2H H C 3 Celebrex H N NH O 2 NHCH3 HCl N MeO C CO Et 2 2 Cl CO2Me MeO Cl S N 2+ )2 Mg N Zoloft N O S - HSO4 Nexium Norvasc Cl Plavix Cl 35 Why Is It So Difficult to Make Drugs? 40 Estimates of the number of possible drug molecules average 10 .
Load more

Recommended publications
  • Annual Meeting and Toxexpo™ TT RANSPARENT RR ELIABLE UU NSURPASSED QUALITY SS ATISFACTION TT IMELY Your Leading Partner for Preclinical Research
    Directory Baltimore, Maryland March 12–16, 2017 56th Annual Meeting and ToxExpo™ TT RANSPARENT RR ELIABLE UU NSURPASSED QUALITY SS ATISFACTION TT IMELY Your Leading Partner for Preclinical Research • Molecular Imaging • Radiochemistry • Luminescence • in vivo, in vitro • Fluorescence • X-Ray, MicroCT • Biomarker Assessment • LC-MS/MS, Multiplex • GLP Toxicology • Acute, subchronic, chronic • PK/PD • ELISA • Histology • Flow Cytometry • Cryo- and Paraffin sections • Safety Pharmacology • Histopathology • Immunohistochemistry • Bioanalytical Chemistry Offices in USA Europe Australia +1 717-798-9990 +49 89 122 287 690 +61 3 9988 1800 [email protected] Booth 2046 AAALAC accredited GLP- compliant Directory SOT Mobile Event App! ToxExpo Hours Access information from the SOT Program, The Monday, March 13 9:15 AM to 4:30 PM Toxicologist, and ToxExpo Directory via your mobile device. Tuesday, March 14 9:15 AM to 4:30 PM Wednesday, March 15 9:15 AM to 4:30 PM Table of Contents Supporters .............................................................................. 2 Exhibit Hall Map ................................................................... 4 2017 Exhibitors ...................................................................... 6 General Information ..........................................................10 Exhibitor-Hosted Sessions ..............................................14 Exhibitor Descriptions .....................................................24 Exhibitor Product/Service Category Listing ........ 128 ToxExpo.com Available
    [Show full text]
  • CONTRACT RESEARCH ORGANIZATIONS (Cros) in ASIA 2014
    CONTRACT RESEARCH ORGANIZATIONS (CROs) in ASIA 2014 Pacific Bridge Medical 7315 Wisconsin Avenue, Suite 609E Bethesda, MD 20814 (301) 469-3400 (301) 469-3409 Email: [email protected] Copyright © 2014 Pacific Bridge Medical. All rights reserved. This content is protected by US and International copyright laws and may not be copied, reprinted, published, translated, resold, hosted, or otherwise distributed by any means without explicit permission. Disclaimer: the information contained in this report is the opinion of Pacific Bridge Medical, a subsidiary of Pacific Bridge, Inc. It is provided for general information purposes only, and does not constitute professional advice. We believe the contents to be true and accurate at the date of writing but can give no assurances or warranties regarding the accuracy, currency, or applicability of any of the contents in relation to specific situations and particular circumstances. TABLE OF CONTENTS CONDUCTING CLINICAL TRIALS IN ASIA ................................................................................ 1 WHY GO TO ASIAN CROS? ..................................................................................................... 1 WHAT TO WATCH OUT FOR .................................................................................................... 2 HOW TO CHOOSE A CRO ......................................................................................................... 3 WHICH COUNTRIES? ...............................................................................................................
    [Show full text]
  • Introduction to Safety Pharmacology
    What is Safety Pharmacology? 2 What is Safety Pharmacology? Safety pharmacology is a branch of pharmacology specializing in detecting and investigating potential undesirable pharmacodynamic effects of new chemical entities (NCEs) on physiological functions in relation to exposure in the therapeutic range and above. Safety pharmacology studies are required to be completed prior to human exposure (i.e., Phase I clinical trials), and regulatory guidance is provided in ICH S7A and other documents. Key Concepts of Safety Pharmacology 4 Systems Primary organ systems (so-called core battery systems) are: • Central Nervous System • Cardiovascular System • Respiratory System Secondary organ systems of interest are: • Gastrointestinal System • Renal System Key aims of safety pharmacology The aims of nonclinical safety pharmacology evaluations are: • To protect Phase I clinical trial volunteers from acute adverse effects of drugs • To protect patients (including patients participating in Phase II and III clinical trials) • To minimize risks of failure during drug development and post-marketing phases due to undesirable pharmacodynamic effects The following key issues have to be considered within safety pharmacology: • The detection of adverse effects liability (hazard identification) • Investigation of the mechanism of effect (risk assessment) • Mitigation strategies (risk management) • Calculating a projected safety margin • Implications for clinical safety monitoring 7 Pharmacology vs. Toxicology? Pharmacology - the study of the action of xenobiotics,
    [Show full text]
  • Baldrick-Biosimilar-2017.Pdf
    Regulatory Toxicology and Pharmacology 86 (2017) 386e391 Contents lists available at ScienceDirect Regulatory Toxicology and Pharmacology journal homepage: www.elsevier.com/locate/yrtph Pharmacokinetic and toxicology comparator testing of biosimilar drugs e Assessing need * Paul Baldrick, PhD Professor, Executive Director, Regulatory Strategy Covance Laboratories Ltd., Otley Road, Harrogate, HG3 1PY, North Yorkshire, United Kingdom article info abstract Article history: A key element in the development of a biosimilar molecule is the comparability of the biological activity/ Received 24 January 2017 nonclinical similarity to the innovator drug. Although some regulatory guidelines are encouraging little Received in revised form or no in vivo testing, currently a common practice is to perform at least one toxicology and/or one 15 April 2017 pharmacokinetic (PK) study to assess if any different findings occur for in-life, clinical pathology and Accepted 18 April 2017 histopathological parameters or in exposure. An exercise was performed in which the results of such Available online 20 April 2017 testing were evaluated. It was found that 10 PK comparison studies in the cynomolgus monkey across 4 monoclonal (Mab) classes showed similar exposure in all cases. In 17 toxicology comparison studies with Keywords: Biosimilar 5 Mab classes performed in the same species and in 7 toxicology comparison studies with non-Mab fi Innovator biosimilars in the rat, no new/unexpected ndings were seen and drug exposure measurement gave Pharmacokinetic testing comparable values in all cases. Overall, although this work does not rule out possible utility of some Toxicology testing in vivo testing (notably in the form of stand-alone PK testing) to confirm similar exposure between the 2 Comparability exercise molecules tested, it is unclear what benefit can be gained from toxicology testing, especially if compa- Regulatory guidance rability has been demonstrated from physiochemical and in vitro characterisation.
    [Show full text]
  • Guidance for Industry, Investigators, and Reviewers: Exploratory IND
    Guidance for Industry, Investigators, and Reviewers Exploratory IND Studies U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) January 2006 Pharmacology/Toxicology G:\7086fnl.doc 12/29/05 Contains Nonbinding Recommendations Guidance for Industry, Investigators, and Reviewers Exploratory IND Studies Office of Training and Communication Division of Drug Information, HFD-240 Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857 (Tel) 301-827-4573 http://www.fda.gov/cder/guidance/index.htm U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) January 2006 Pharmacology/Toxicology Contains Nonbinding Recommendations TABLE OF CONTENTS I. INTRODUCTION............................................................................................................. 1 II. BACKGROUND ............................................................................................................... 2 A. Traditional Phase 1 Approach......................................................................................................2 B. Exploratory IND Approach ..........................................................................................................3 III. CONTENT OF IND SUBMISSIONS ............................................................................. 5 A. Clinical Information ......................................................................................................................5
    [Show full text]
  • Handbook Non-Clinical Safety Testing
    UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) HANDBOOK NON-CLINICAL SAFETY TESTING This Handbook on Non-clinical Safety Testing is designed to serve as an aid for scientists who wish to undertake non-clinical safety testing for regulatory purposes during product development. It has been developed as part of a significant and wide- ranging technology transfer and capacity building programme in the area of pre-clin- ical product development for disease endemic countries. The Non-clinical Safety Testing Handbook was produced by a Scientific Working Group (SWG) on pre-clinical issues, convened by the UNICEF/UNDP/World Bank/WHO Special Programme for Research & Training in Tropical Diseases (TDR) and consisting of independent scientific specialists from around the world. The Handbook is broadly based on current safety testing guidelines including those of the Organisation for Eco- nomic Cooperation and Development (OECD) and the International Conference on Harmonisation (ICH). The Handbook will provide scientists and laboratories in disease endemic countries with the necessary technical aid for planning and implementing non-clinical safety testing programmes. The Handbook attempts to highlight the differences between syn- thetic chemical drug, vaccine and traditional herbal (botanical) medicine development programmes. TDR gratefully acknowledges the participation and support of all those involved in the production of this Handbook. For all correspondence: Dr Deborah Kioy Pre-clinical Coordinator Product Research and Development TDR/WHO Avenue Appia 20 1211 Geneva 27 – Switzerland Tel: +41 22 791 3524 Fax: +41 22 791 4854 E-mail: [email protected] TABLE OF CONTENTS FOREWORD .
    [Show full text]
  • Regulatory Toxicology
    Regulatory Toxicology Regulatory (Pharmaceutical) Toxicology Ruth Roberts Director, ApconiX Ltd Chair of Drug Discovery, University of Birmingham, UK Conflict of Interest Declaration Ruth Roberts is co-founder and co-director of Apconix, an integrated toxicology and ion channel research company that provides expert advice on nonclinical aspects of drug discovery and drug development to academia, industry, government and not-for-profit organisations. Overview/Objectives • Outline and purpose of regulatory • Outline of general toxicology testing toxicology testing for pharmaceuticals for agrochemicals and general • Overall design of the package from first time chemicals in humans (FTIH) through to marketing authorisation • Challenges and opportunities • Translation • Purpose: ensuring volunteer and patient safety in clinical trials • Attrition • Assumptions to challenge • Decision making • In vitro replacements • General Toxicology • Future Perspectives • Maximum tolerated dose (MTD)/Dose Range Finding (DRFs), “pivotal” and chronic toxicology studies • Design (doses, species, duration) and outcome • Regulatory documentation Regulatory Toxicology: Learning Objectives • Understand the purpose of pharmaceutical toxicology • Understand the pivotal role played by general toxicology studies in protecting volunteer and patient safety • Understand common principles with other sectors (agrochemicals, general chemicals) • Understand outcome of general toxicology studies and the principles and caveats of their designs • Understand the global framework
    [Show full text]
  • Bioanalytical Systems, Inc
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) _ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended September 30, 2020. OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ___________ to _____________. Commission File Number 000-23357 BIOANALYTICAL SYSTEMS, INC. (Exact name of the registrant as specified in its charter) INDIANA 35-1345024 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 2701 KENT AVENUE WEST LAFAYETTE, INDIANA 47906 (Address of principal executive offices) (Zip code) (765) 463-4527 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbols Name of exchange on which registered Common Shares BASi NASDAQ Capital Market Securities registered pursuant to section 12(g) of the Act: None Indicate by checkmark if the registrant is a well-known seasoned issuer, as defined by Rule 405 of the Securities Act. YES NO _ Indicate by checkmark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES NO _ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Recent Efforts to Elucidate the Scientific Validity of Animal-Based
    Bailey and Balls BMC Medical Ethics (2019) 20:16 https://doi.org/10.1186/s12910-019-0352-3 DEBATE Open Access Recent efforts to elucidate the scientific validity of animal-based drug tests by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations Jarrod Bailey1* and Michael Balls2 Abstract Background: Even after several decades of human drug development, there remains an absence of published, substantial, comprehensive data to validate the use of animals in preclinical drug testing, and to point to their predictive nature with regard to human safety/toxicity and efficacy. Two recent papers, authored by pharmaceutical industry scientists, added to the few substantive publications that exist. In this brief article, we discuss both these papers, as well as our own series of three papers on the subject, and also various views and criticisms of lobby groups that advocate the animal testing of new drugs. Main text: We argue that there still remains no published evidence to support the current regulatory paradigm of animal testing in supporting safe entry to clinical trials. In fact, the data in these recent studies, as well as in our own studies, support the contention that tests on rodents, dogs and monkeys provide next to no evidential weight to the probability of there being a lack of human toxicity, when there is no apparent toxicity in the animals. Conclusion: Based on these data, and in particular on this finding, it must be concluded that animal drug tests are therefore not fit for their stated purpose. At the very least, it is now incumbent on—and we very much encourage—the pharmaceutical industry and its regulators to commission, conduct and/or facilitate further independent studies involving the use of substantial proprietary data.
    [Show full text]
  • In Silico and in Vitro Testing Resources Alcyomics, Ltd., Offers In
    In Silico and In Vitro Testing Resources Alcyomics, Ltd., offers in vitro human-based pre-clinical drug safety testing. It manufactures SkimuneTM (human skin explants for safety and efficacy testing) and offers immunogenicity services, efficacy testing of immunomodulators, hypersensitivity testing, potency assessment, cellular and cytokine assays and safety assessment services. AllCells, LLC, offers more than 150 primary cell types and related RNA and cDNA from normal and disease-state tissues.Cell types include stem cells (progenitor, CD34+, etc.), hematopoietic, human hematologic disease, endothelial, dendritic, HUVEC cells and many others. It also offers services such as drug discovery, device validation, flow cytometry and cell sorting, tissue culture protein analysis and genotyping as well as stem cell and immune assays. Alternative Toxicity Services offers high-content screening for evidence-based acute general toxicity and neurotoxicity. APSciences, Inc., offers Integrated Discrete Multiple Organ Co-culture (IdMOC) technology, which is an in vitro model consisting of multiple, inner wells within a larger interconnecting chamber. It is based on the concept that the multiple organs in a human (or other animal) are physically separated but interconnected by the systemic circulation (i.e., blood). IdMOC can be used to evaluate drug toxicity, drug metabolism and drug distribution as well as anti-cancer drugs for cytotoxicity, efficacy and mechanism of action. Asterand, PLC, provides high quality, well characterised human tissue through its worldwide network of 75 active collaborative donor institutions and human tissue-based research solutions to drug discovery scientists. It also provides a collaborative scientific approach to deliver human tissue-based data ontarget and biomarker validationas well ascompound potency, effect and safety.
    [Show full text]
  • Toxexpo Directory
    ToxExpoTM Directory 54th Annual Meeting & ToxExpoTM March 22–26, 2015 San Diego Convention Center San Diego, California TRANSLATING DISCOVERIES Reaching the clinic can be a daunting task. Let the experts at Charles River be your guide, every step of the way. Our expansive safety assessment portfolio is supported by advanced imaging and biomarker services that provide a deep scientific understanding of your compound and produce the high quality data you need to optimize your drug development program. Visit us at booth 1326 to learn more. every step of the way. www.criver.com/SOT2015 ToxExpo Directory Table of Contents ToxExpo Exhibit Hall Hours Supporters .......................................................................... 2 Monday, March 23 9:00 AM–4:30 PM Exhibit Hall Map ...............................................................4 2015 Exhibitors ..................................................................6 Tuesday, March 24 8:30 AM–4:30 PM General Information ....................................................... 10 Wednesday, March 25 8:30 AM–4:30 PM Exhibitor-Hosted Sessions ...........................................14 Exhibitor Descriptions ..................................................22 Exhibitor Product/Service Category Listing ....... 136 Follow us on Twitter at @ToxExpo and @SOToxicology Recording, Photography, and Cell Phone Policy SOT Badge Policy—altering of SOT badges in any way is strictly prohibited. All attendees must be officially registered • Photographing exhibit booths is prohibited. for the
    [Show full text]
  • Pharmacology, Toxicology & Pharmaceutical Science
    PHARMACOLOGY, TOXICOLOGY & PHARMACEUTICAL SCIENCE 2017 CATALOG 1 Elsevier Science and Technology Books deliver targeted content that enables the understanding and application of research. Year after year readers use our books to drive advancements in their fields. Tools and content on ScienceDirect offer: • Full-text version online or • Portable content available on download and print with no computers, tablets and smartphones digital rights management to give users information in the restrictions (DRM) format that best suits their needs • Multi-user/concurrent • Integrated book and journal access at any time from any content for easier access to related location to expand the reach materials of the content to your patrons • Free MARC records to drive discoverability and usage Our foundational content—including Reference Modules, unique resources that are trustworthy, current, discoverable, and hosted on ScienceDirect—complements original research in journal articles. Our Legacy Collection on ScienceDirect, in 20 subject areas, ensures that valuable historical content is discoverable and searchable, saving time and resources. Table of Contents Stay Connected Biomedical Science & Medicine.........................................2 Stay connected with Life Sciences........................................................................6 Elsevier on Facebook, Twitter, YouTube and Serials.................................................................................58 LinkedIn. These sites are full of news, resources, Titles Index.........................................................................67
    [Show full text]